{"id":"NCT03761537","sponsor":"LEO Pharma","briefTitle":"Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre, Phase 3 Trial Investigating the Efficacy, Safety, and Tolerability of Tralokinumab Administered in Combination With Topical Corticosteroids to Adult Subjects With Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-13","primaryCompletion":"2020-04-21","completion":"2020-09-28","firstPosted":"2018-12-03","resultsPosted":"2021-10-26","lastUpdate":"2025-03-11"},"enrollment":277,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tralokinumab + TCS","type":"EXPERIMENTAL"},{"label":"Placebo + TCS","type":"PLACEBO_COMPARATOR"}],"summary":"Primary objective:\n\nTo demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have contraindications to oral cyclosporine A (CSA).\n\nSecondary objectives:\n\nTo evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life compared to placebo in combination with TCS.\n\nTo evaluate the safety of tralokinumab in combination with TCS when treating severe AD in subjects who are not adequately controlled with or have contraindications to oral CSA compared to placebo in combination with TCS.","primaryOutcome":{"measure":"At Least 75% Reduction in Eczema Area and Severity Index (EASI75) From Week 0 to Week 16","timeFrame":"Week 0 to Week 16","effectByArm":[{"arm":"Tralokinumab+TCS","deltaMin":64.2,"sd":null},{"arm":"Placebo+TCS","deltaMin":50.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.018"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":74,"countries":["Belgium","Czechia","France","Germany","Poland","Spain","United Kingdom"]},"refs":{"pmids":["40879371"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":138},"commonTop":["Viral upper respiratory tract infection","Headache","Dermatitis atopic","Upper respiratory tract infection","Asthma"]}}